Biopharmaceutical News and Research

RSS

Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.

People inherit different versions of any particular gene, and some genes affect how patients process and metabolize medicines. This especially holds true for people with cardiovascular (CV) disease. They may be fast, slow or non-metabolizers and might also react badly (with serious adverse events) to certain drug therapies or not at all.

27 Nov 2013

UMass Medical School licenses "anti-gal" technology to Agalimmune

The University of Massachusetts Medical School has licensed "anti-gal" technology developed by Professor of Surgery and Medicine Uri Galili, PhD, to newly formed biopharmaceutical company Agalimmune Ltd. for the purpose of developing innovative immunotherapies for the treatment of solid tumor cancers. Agalimmune is supported by an investment group comprising Loxbridge Research LLP and Animatrix Capital LLP and is based in London and California.

27 Nov 2013

Agalimmune established to develop innovative immunotherapeutics for treatment of cancer

Agalimmune Ltd, a biopharmaceutical company, has been created to develop innovative immunotherapeutics for the treatment of cancer, with a focus on solid tumours.

26 Nov 2013

Researchers identify new form of treatment for brain tumor

Glioblastoma is one of the most ominous brain tumors. Despite aggressive surgery, radiation and chemotherapy the outcome of this disease is almost always fatal.

26 Nov 2013

Arrowhead seeks approval to start ARC-520 phase 2a trial for chronic hepatitis B infection

Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it recently filed an application for approval to begin a phase 2a clinical trial of its RNAi-based therapeutic candidate, ARC-520, for the potential treatment of chronic hepatitis B virus infection.

25 Nov 2013

Vect-Horus, AAA form scientific collaboration to open new avenues in treatment of brain diseases

Vect-Horus, a French company specialized in the development of vector molecules for the central nervous system, announces today it has signed a scientific collaboration agreement with Advanced Accelerator Applications, a fast growing international player in Molecular Nuclear Medicine. The financial terms of the deal have not been disclosed.

20 Nov 2013

NeutroPhase irrigation therapy and NPWT help treat severe flesh eating and wound infections

NovaBay Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, today announced the publication of a scientific paper by Dr. John R. Crew of Seton Medical Center, Daly City, California, describing the first use of adjunctive NeutroPhase irrigation therapy in conjunction with Negative Pressure Wound Therapy to successfully manage the severely-infected wound in the arm of a patient with life-threatening 'flesh-eating' disease.

20 Nov 2013

Atopix recruits first patient in OC459 Phase 2 trial for treatment of atopic dermatitis

Atopix Therapeutics Ltd, a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, announced the recruitment of the first patient in a six month Phase 2 clinical trial of its lead compound OC459 in moderate-to-severe atopic dermatitis (eczema).

19 Nov 2013

Kiadis reports successful Phase II enrollment for CR-AIR-007 ATIR blood cancer treatment study

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces the successful Phase II enrollment of approximately ten patients of whom the majority have already been transplanted and received ATIR™. Kiadis Pharma's lead program, ATIR™, is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for blood cancer patients who do not have a standard of care stem cell donor available. Topline data from the trial (CR-AIR-007) is expected in the first half of 2014.

18 Nov 2013

New report addresses many changes that transform Medical Education landscape

Medical Education groups are often being transformed by regulatory and budget pressures, making it increasingly difficult to effectively educate healthcare practitioners on the safe and effective use of products. With the pressure to reduce budgets increasing within the pharmaceutical and medical device industries, it is absolutely critical for Medical Education groups to find practical and economical methods of reaching healthcare professionals.

16 Nov 2013

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced final efficacy and safety data from its recently completed Phase 2 study of beloranib, a selective inhibitor of methionine aminopeptidase 2.

15 Nov 2013

TPI’s revenue decreases 8.1% to $14.8 million in first quarter fiscal year 2014

Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the first quarter fiscal year 2014.

15 Nov 2013

ACADIA Pharmaceuticals initiates pimavanserin Phase II trial in ADP patients

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it has initiated a Phase II feasibility trial designed to examine the efficacy and safety of pimavanserin as a treatment for patients with Alzheimer's disease psychosis.

15 Nov 2013

Merck Serono signs co-development and commercialization agreement for BeiGene-290

Merck Serono, the biopharmaceutical division of Merck, today announced that a global licensing, co-development, and commercialization agreement for BeiGene-290 has been signed with BeiGene Co., Ltd., a biotech research and development company in Beijing, China.

13 Nov 2013

Orexigen Therapeutics reports net loss of $18.6 million in Q3 2013

Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced business and financial results for the third quarter ended September 30, 2013.

12 Nov 2013

Zalicus announces top-line results from Z160 Phase 2 clinical studies in chronic pain indications

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced top-line results from two Phase 2 clinical studies of Z160 in chronic pain indications.

11 Nov 2013

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

GW Pharmaceuticals plc a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme.

11 Nov 2013

New treatment option for patients with most difficult-to-treat forms of hepatitis C

A novel single-pill combination drug could present a new treatment option for patients with the most difficult-to-treat forms of hepatitis C, according to the results of a Phase 2 trial, published in The Lancet.

6 Nov 2013

Bioniche Life Sciences announces financial results for first quarter of Fiscal 2014

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for the first quarter of Fiscal 2014 (ended September 30, 2013).

6 Nov 2013

Sound Pharmaceuticals completes enrollment for SPI-1005 Phase 2 clinical trial

Sound Pharmaceuticals has successfully completed enrollment of its Phase 2 clinical trial with SPI-1005 at the University of Florida. This study enrolled 80 healthy subjects with normal or slight hearing loss and exposed the volunteer to calibrated music using an iPod and insert earphones.

5 Nov 2013

Biopharmaceutical News and Research

Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.

UMass Medical School licenses "anti-gal" technology to Agalimmune

Agalimmune established to develop innovative immunotherapeutics for treatment of cancer

Researchers identify new form of treatment for brain tumor

Arrowhead seeks approval to start ARC-520 phase 2a trial for chronic hepatitis B infection

Vect-Horus, AAA form scientific collaboration to open new avenues in treatment of brain diseases

NeutroPhase irrigation therapy and NPWT help treat severe flesh eating and wound infections

Atopix recruits first patient in OC459 Phase 2 trial for treatment of atopic dermatitis

Kiadis reports successful Phase II enrollment for CR-AIR-007 ATIR blood cancer treatment study

New report addresses many changes that transform Medical Education landscape

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

TPI’s revenue decreases 8.1% to $14.8 million in first quarter fiscal year 2014

ACADIA Pharmaceuticals initiates pimavanserin Phase II trial in ADP patients

Merck Serono signs co-development and commercialization agreement for BeiGene-290

Orexigen Therapeutics reports net loss of $18.6 million in Q3 2013

Zalicus announces top-line results from Z160 Phase 2 clinical studies in chronic pain indications

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

New treatment option for patients with most difficult-to-treat forms of hepatitis C

Bioniche Life Sciences announces financial results for first quarter of Fiscal 2014

Sound Pharmaceuticals completes enrollment for SPI-1005 Phase 2 clinical trial

Event guide: World ADC San Diego eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News